nach oben

Reactions Weekly

Erschienen in:

01.10.2019 | Case report

Capecitabine/temozolomide

Hand-foot syndrome: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

In a retrospective review of the patients, who received capecitabine and temozolomide (CAPTEM regimen) for metastatic lung neuroendocrine neoplasms between January 2008 and September 2018, one patient was described [age and sex not stated], who developed hand-foot syndrome. The patient started receiving capecitabine and temozolomide [routes and dosages not stated]. Subsequently, the patient developed hand-foot syndrome [durations of treatments to reaction onset not stated]. Therefore, the doses of capecitabine and temozolomide were reduced [outcome not stated]. …

Al-Toubah TE, et al. Retrospective study of capecitabine and temozolomide in advanced lung neuroendocrine neoplasms. Journal of Clinical Oncology 37 (Suppl. 15): abstr. 8542, May 2019. Available from: URL: https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.8542 [abstract] - USA

Titel: Capecitabine/temozolomide
Hand-foot syndrome: case report
Publikationsdatum: 01.10.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-68834-z

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Methotrexate

Lanthanum carbonate

Doxorubicin

Cyclophosphamide/docetaxel/doxorubicin

Carbamazepine/diazepam/quetiapine

Multiple drugs